BB's Stock Haven

[cngreen]

Heres the link. http://www.ludlowcapital.com/reports/cehc.html looks good on the upside

Ludlow Capital Group Updates Research Opinion on Cephas Holding Corp. (CEHC), Upgrades Price Target of $0.15 to $0.20 per share
Last Updated: March 07, 2009 - 11:25am EST

(NEW YORK)-- Ludlow Capital Group, Inc updates research opinion on Cephas Holding Corp. (OTC: CEHC), a diversified investment holding company, maintains a 'speculative' B+ rating, price target of $0.15 to $0.20 per share.

SUMMARY

Cephas Holding Corp. is a diversified venture holding corporation focused on three business segments covering mobile gaming, stem cell treatment, and alternative energy projects. The Company has around 76 million shares still issued and outstanding, giving the Company a market cap well below $1 million.

Project #1: Stem Cell Treatment Company

Overview

The stem cell company is based in Tampa, FL, and has been treating patients for the last four years for such serious chronic diseases including ALS, Alzheimer's, Parkinsonism, multiple sclerosis, autism, post stroke, brain damage, diabetes, heart disease, advanced kidney disease, COPD, scleroderma, lupus, rheumatoid arthritis, Crohn's, advanced cancer, transverse myeltis, etc.

Financial Earnings

For fiscal year 2008, the Company posted total revenues of around $3 million (unaudited), and is currently profitable and cash flow positive.

Operation Centers

The Company currently treats patients in its Tampa, Florida facility for anti-aging medicine (bio-identical hormones, immunological, cardiac, pulmonary, and metabolic workups), as well as treatments involving autologous stem cells.

Internationally, the company operates, with Government approval, facilities in Mexico, and Lima, Peru. In these out of country locations patients are treated with specific organ stem cells extracted from umbilical cord blood for the serious diseases listed above. The Company is seeking to expand operations with new stem cell treatment centers around the world.

Umbilical Cord Stem Cells Treatment

The Company focuses on the use of umbilical cord stem cells in the treatment of a wide variety of disorders. The availability of umbilical cord blood makes this an appropriate source for stem cells. All donors are carefully screened to rule out HIV, Hepatitis B and C and a variety of other contagious conditions.

The stem cells are extracted from the umbilical cord blood and placed into culture for several weeks. During this time specific agents are added in the culture which will direct the stem cells to become early differentiated heart stem cells; pancreas stem cells that secrete insulin(for diabetes); pulmonary(lung) stem cells; kidney stem cells; neuron stem cells(for Parkinsonism, Alzheimer’s, Autism, Stroke, Brain Damage, spinal cord injury, multiple sclerosis); muscle stem cells; hematopoietic stem cells(for blood diseases).

These types of stem cells may also be incorporated and mixed with immunological cells such as T lymphocytes, T regulatory cells, T cytotoxic cells, Natural killer cells, anti-cytokines, anti-interleukins to treat autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma and Crohn’s disease.

Adult Stem Cells Treatment

Adult stem cells are in every organ of our body; heart, brain, lung, kidney, pancreas, spinal cord, eyes, gastrointestinal tract. They are essential in repair of injured and diseased tissues. However, in various injuries and disease the extent of the problem is overwhelming and insufficient numbers of adult stem cells cannot correct the problem.

A new form of treatment that the Company offers is that of administration of the patient’s own stem cells back into their body. The patient’s own blood sample (or in some cases) a sample of their bone marrow is sent to our laboratory The laboratory extracts out adult stem cells from this sample and expands them into millions of cells. Approximately a week later these are then sent back to the patient’s physician for administration. Patients may also have this procedure done at one of their treatment centers in California or Florida.

The Company considers the procedure safe since it involves the use of the patient’s own stem cells so that there is no problem with engraftment or rejection. The procedure should be considered for any major serious medical disorder or injury; also as part of an anti-aging medicine regime.

Anti-Aging Division

The Company will also begin selling anti-aging oral products for prevention of cardiac disease, lung disorders, diabetes and neurodegenerative diseases such as ALS, multiple sclerosis, Parkinsonism and Alzheimer's as well as anti-aging skin creams. The company plans to submit for patenting its protocol for pancreatic stem cells that produce insulin and its neuron stem cells that secrete dopamine.

Example Patient Case Studies

Case#1: A 65 year old had a history of marked Diabeties (Type 1) that required him to take large doses of insulin, with blood sugars levels initially at 850. The patient received two treatments of pancreatic stem cells that produced insulin. Following the patients stem cell transplant his requirements are now minimal, and his blood sugar is now in the range of 74.

Case#2: A 44 year old male, spinal cord injury, received neuron stem cells and nerve growth factors at site of injury, and now undergoing intensive physical therapy rehabilitation with future use of trigger point electric stimulation and use of a fes bike, possible future candidate for sacral nerve bladder pacemaker.

The name of the Company is being withheld so as to protect both parties until a final agreement can be hashed out, as well as Ludlow BioVentures' consulting interest in this deal. To learning more about this investment project please register online to receive an investor packet.